Medical Oncology Associates, PS

Spokane, Washington 99208-1129

1 studies enrolling now · 26 studies all time

What they study most

Adenocarcinoma of Lung, Adenocarcinoma of the Lung, Advanced Prostate Cancer, Advanced Solid Tumors, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Chemotherapy-induced Thrombocytopenia, Chronic Lymphocytic Leukemia, Colorectal Cancer, Colorectal Cancer (CRC), Endometrial Cancer

Studies at this site

• A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) — Recruiting now
• GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors — Running, not enrolling
• Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression — Completed
• Connect® MM- The Multiple Myeloma Disease Registry — Stopped early
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer — Running, not enrolling
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer — Completed
• Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma — Completed
• QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA — Completed
• Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas — Stopped early
• An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung — Stopped early
• Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) — Stopped early
• FPA150 in Patients With Advanced Solid Tumors — Stopped early
• PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) — Completed
• Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer — Completed
• Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Completed
• Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency — Completed
• Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer — Completed
• A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung — Completed
• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer — Stopped early
• Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry — Completed
• Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck — Completed
• A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer — Completed
• A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer — Stopped early
• Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer — Stopped early
• A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer — Stopped early
• Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer — Stopped early